Hong Kong Stocks Movement | B&K CORP-B (02396) Plunges Over 12% in Morning Session to Record Low, Now Halved from IPO Price

Stock News2025-12-30

B&K CORP-B (02396) slumped more than 12%, hitting a low of HK$18.6 to set a new record low since its listing, and has now halved from its initial public offering price of HK$38.2. As of the time of writing, the stock was down 11.77%, trading at HK$18.67, with a turnover of HK$7.462 million.

B&K CORP-B is a biopharmaceutical company focused on the discovery, development, and commercialization of wound healing therapies. As of December 5, 2025, the company's pipeline includes ten candidate products, seven of which are PDGF-based candidate drugs, covering two core products: Pro-101-1 and Pro-101-2.

Financially, the company has not yet generated any revenue from product sales. In 2023, 2024, and for the period ended September 30, 2025, the company reported net losses of RMB 110 million, RMB 210 million, and RMB 130 million, respectively. The vast majority of these net losses were attributable to research and development expenses and administrative costs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112596904?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-30 11:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112596904","market":"hk","top_or_hot":-1,"title":"Hong Kong Stocks Movement | B&K CORP-B (02396) Plunges Over 12% in Morning Session to Record Low, Now Halved from IPO Price","media":"Stock News","content":"<p>B&K CORP-B (02396) slumped more than 12%, hitting a low of HK$18.6 to set a new record low since its listing, and has now halved from its initial public offering price of HK$38.2. As of the time of writing, the stock was down 11.77%, trading at HK$18.67, with a turnover of HK$7.462 million.</p>\n<p>B&K CORP-B is a biopharmaceutical company focused on the discovery, development, and commercialization of wound healing therapies. As of December 5, 2025, the company's pipeline includes ten candidate products, seven of which are PDGF-based candidate drugs, covering two core products: Pro-101-1 and Pro-101-2.</p>\n<p>Financially, the company has not yet generated any revenue from product sales. In 2023, 2024, and for the period ended September 30, 2025, the company reported net losses of RMB 110 million, RMB 210 million, and RMB 130 million, respectively. The vast majority of these net losses were attributable to research and development expenses and administrative costs.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stocks Movement | B&K CORP-B (02396) Plunges Over 12% in Morning Session to Record Low, Now Halved from IPO Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stocks Movement | B&K CORP-B (02396) Plunges Over 12% in Morning Session to Record Low, Now Halved from IPO Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-30 11:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>B&K CORP-B (02396) slumped more than 12%, hitting a low of HK$18.6 to set a new record low since its listing, and has now halved from its initial public offering price of HK$38.2. As of the time of writing, the stock was down 11.77%, trading at HK$18.67, with a turnover of HK$7.462 million.</p>\n<p>B&K CORP-B is a biopharmaceutical company focused on the discovery, development, and commercialization of wound healing therapies. As of December 5, 2025, the company's pipeline includes ten candidate products, seven of which are PDGF-based candidate drugs, covering two core products: Pro-101-1 and Pro-101-2.</p>\n<p>Financially, the company has not yet generated any revenue from product sales. In 2023, 2024, and for the period ended September 30, 2025, the company reported net losses of RMB 110 million, RMB 210 million, and RMB 130 million, respectively. The vast majority of these net losses were attributable to research and development expenses and administrative costs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02396","symbol_name":"华芢生物-B","start_time":0,"source_url":"","article_id":"1112596904","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112596904","pubTimestamp":1767065296,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"B&K CORP-B (02396) slumped more than 12%, hitting a low of HK$18.6 to set a new record low since its listing, and has now halved from its initial public offering price of HK$38.2. As of the time of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02396":"华芢生物-B"},"translate_title":"港股动向|B&K CORP-B(02396)早盘急跌超12%创历史新低现较招股价腰斩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02396":1},"content_text":"B&K CORP-B (02396) slumped more than 12%, hitting a low of HK$18.6 to set a new record low since its listing, and has now halved from its initial public offering price of HK$38.2. As of the time of writing, the stock was down 11.77%, trading at HK$18.67, with a turnover of HK$7.462 million.\nB&K CORP-B is a biopharmaceutical company focused on the discovery, development, and commercialization of wound healing therapies. As of December 5, 2025, the company's pipeline includes ten candidate products, seven of which are PDGF-based candidate drugs, covering two core products: Pro-101-1 and Pro-101-2.\nFinancially, the company has not yet generated any revenue from product sales. In 2023, 2024, and for the period ended September 30, 2025, the company reported net losses of RMB 110 million, RMB 210 million, and RMB 130 million, respectively. The vast majority of these net losses were attributable to research and development expenses and administrative costs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112596904","isCrawlerRequest":true}